Iovance Biotherapeutics ( (IOVA) ) has released its Q3 earnings. Here is a breakdown of the information Iovance Biotherapeutics presented to its investors.
Don't Miss Our Christmas Offers:
- Discover the latest stocks recommended by top Wall Street analysts, all in one place with Analyst Top Stocks
- Make smarter investments with weekly expert stock picks from the Smart Investor Newsletter
Iovance Biotherapeutics, Inc. is a commercial biotechnology company specializing in the development and delivery of tumor-infiltrating lymphocyte (TIL) therapies for cancer patients, with a focus on innovative treatments for solid tumors.
In its latest earnings report, Iovance Biotherapeutics highlighted significant demand for its flagship product, Amtagvi™, which resulted in $58.6 million in total product revenue for the third quarter of 2024. The company is poised for continued revenue growth with reaffirmed guidance for fiscal years 2024 and 2025.
The company achieved $42.1 million in revenue from Amtagvi sales and $16.5 million from Proleukin in Q3 2024, with year-to-date product revenue totaling $90.4 million. Iovance projects total product revenue between $160-$165 million for FY24 and $450-$475 million for FY25. Additionally, manufacturing capacity expansion and regulatory submissions in Europe and Canada are underway, aiming to capture global market share.
Iovance is actively expanding its clinical pipeline with ongoing trials in non-small cell lung cancer and endometrial cancer, among other indications. The company also reports progress in developing next-generation TIL therapies, aiming to enhance treatment efficacy and safety.
Looking forward, Iovance Biotherapeutics anticipates further growth driven by increased adoption of Amtagvi and Proleukin, expansion into new markets, and advancements in its clinical programs, positioning itself as a leader in the TIL therapy space.
